Isofol Medical (ISOFOL) Q1 2026 earnings summary

Executive summary

• Reinforced financial position through high warrant exercise rate and guarantee commitment, raising nearly SEK 19 million before costs.

• Regulatory progress with approval of an optimized phase Ib/II study design, broadening inclusion criteria and adding a comparative arm.

• Promising preliminary results from the ongoing phase Ib/II study in metastatic colorectal cancer, with all evaluated patients responding and half considered for tumor surgery.

• Extended global license for arfolitixorin to include autism spectrum disorder, with exploratory preclinical work initiated.

• Continued scientific visibility through participation in major international oncology conferences.

Financial highlights

• Net revenue was SEK 0 (0) for the quarter.

• Operating loss increased to SEK -15.6 million from SEK -14.1 million year-over-year.

• Result after financial items was SEK -15.1 million compared to SEK -13.7 million in Q1 2025.

• Cash and cash equivalents at March 31, 2026, were SEK 110.7 million, up from SEK 82.1 million a year earlier.

• Cash flow from operating activities was SEK -16.4 million, a larger outflow than SEK -12.8 million in Q1 2025.

Outlook and guidance

• Adequate funding secured for planned operations over the next 12 months.

• Recruitment for the ongoing clinical study is expected to accelerate with the addition of new study centers and broadened criteria.

• Continued focus on advancing arfolitixorin in oncology, with optionality for expansion into autism spectrum disorder.